Abstract: Indolotryptoline compounds of the general structure: are disclosed. In these compounds R1 is chosen from hydrogen, halogen and OH; R2 is (C1-C4)alkoxy; and R3 is chosen from hydrogen and halogen The compounds are useful for treating cancer.
Abstract: The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.
Type:
Application
Filed:
January 30, 2015
Publication date:
June 21, 2018
Applicants:
The Rockefeller University, California Institute of Technology
Inventors:
Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf, Johannes Scheid
Abstract: The present invention relates to anti-tumor agents that target certain tumor-associated macrophages. Also disclosed are methods of using such agents in treatment of cancer.
Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
Abstract: The present invention relates to immunogenic immune complexes, related compositions, and related methods. This invention addresses the above-described un-met need by providing an immune complex (IC) or immune complexes (ICs), which take advantages of Type II Fc receptor (FcR) interactions and signaling to elicit broader and more potent protective immune responses. In one aspect, the invention provides an immune complex comprising an antigenic agent and an isolated protein. The protein comprises an IgG Fc region and is capable of binding to a Type II Fc receptor. Preferably, the protein is an antibody or an Fc region-containing fragment thereof.
Type:
Application
Filed:
March 21, 2016
Publication date:
May 3, 2018
Applicant:
The Rockefeller University
Inventors:
Jeffrey V. Ravetch, Taia Wang, Jad Mamaary
Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
Type:
Application
Filed:
September 29, 2017
Publication date:
March 22, 2018
Applicants:
The Rockefeller University, California Institute of Technology
Inventors:
Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.
Type:
Grant
Filed:
April 14, 2015
Date of Patent:
March 13, 2018
Assignee:
THE ROCKEFELLER UNIVERSITY
Inventors:
Vincent A. Fischetti, Jonathan Schmitz, Daniel Gilmer, Chad Euler
Abstract: The present invention provides isolated dimeric Streptococcus-specific phage lysins having two Streptococcus-specific phage lysin monomers covalently linked to each other, and having killing activity against one or more Streptococcus bacteria. Also provided for are pharmaceutical compositions of dimeric lysins and their use in therapeutic treatment or alleviation of infections or bacterial colonizations. The dimeric lysins may also be used to decontaminate porous and non-porous surfaces or devices.
Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
Type:
Grant
Filed:
July 25, 2012
Date of Patent:
February 13, 2018
Assignees:
California Institute of Technology, The Rockefeller University
Inventors:
Ron Diskin, Pamela J. Bjorkman, Michel Nussenzweig, Johannes Scheid
Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.
Type:
Grant
Filed:
June 21, 2013
Date of Patent:
January 30, 2018
Assignees:
California Institute of Technology, The Rockefeller University
Inventors:
Ron Diskin, Anthony P. West, Michel C. Nussenzweig, Pamela J. Bjorkman
Abstract: The present disclosure provides antibodies that specifically bind to Mer Tyrosine Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK) and compositions comprising such antibodies, wherein said antibody agonizes MERTK signaling on endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody that specifically binds to MERTK and agonizes MERTK signaling on endothelial cells.
Type:
Application
Filed:
December 21, 2015
Publication date:
January 4, 2018
Applicant:
The Rockefeller University
Inventors:
Sohail Tavazoie, Nils Halberg, Masoud Tavazoie
Abstract: This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods.
Abstract: The present disclosure provides, among other things, novel cyclic-GMP-AMP (cGAMP) analogs, mimics, mimetics and variants, and compositions and kits thereof; methods of using the compounds as described herein for treating cancer, and immune disease, disorders, or conditions; methods of using the compounds as described herein for modulating cGAS and STING; and methods of designing or characterizing a cGAS modulator.
Type:
Grant
Filed:
April 29, 2014
Date of Patent:
December 12, 2017
Assignees:
Memorial Sloan Kettering Cancer Center, Rutgers, The State University of New Jersey, The Rockefeller University, University of Bonn
Inventors:
Dinshaw Patel, Thomas Tuschl, Manuel Ascano, Jr., Yang Wu, Yizhou Liu, Winfried Barchet, Gunther Hartmann, Thomas Zillinger, Roger Jones, Barbara L. Gaffney, Pu Gao
Abstract: Anthracyclin compounds of the general structure: are disclosed. In these compounds R1 is methyl, acetyl or hydroxyacetyl; R2-R5 and R10-R13 are independently H or methyl; R6 R7 and R8 are independently H, OH or OCH3; and n is zero or one. The compounds are useful for treating cancer.
Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.
Type:
Grant
Filed:
January 7, 2016
Date of Patent:
November 21, 2017
Assignees:
The Broad Institute Inc., Massachusetts Institute of Technology, The Rockefeller University
Inventors:
Feng Zhang, David Benjamin Turitz Cox, Luciano Marraffini, David Olivier Bikard, Wenyan Jiang, Neville Espi Sanjana